Phase 4
N=201
Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
Percutaneous Coronary Intervention
Bottom Line
View on ClinicalTrials.gov: NCT03557385 ↗Enrolled (actual)
201
Serious AEs
3.0%
Results posted
Apr 2024
Primary outcome: Primary: Comparison Between Contrast Fractional Flow Reserves (cFFR) and Adenosine Fractional Flow Reserves (aFFR) — 0.8922 proportion of lesions with agreement
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Iopamidol (Drug); adenosine (Drug); Navvus® Catheter (Device); CVi® Contrast Delivery System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparison Between Contrast Fractional Flow Reserves (cFFR) and Adenosine Fractional Flow Reserves (aFFR) |
0.8922 | — |
| PRIMARY Qualitative Method Comparison Between Contrast Fractional Flow Reserves and Adenosine Fractional Flow Reserves |
0.8912 | — |
| SECONDARY Long-term Clinical Outcomes: Composite Major Adverse Cardiac Events (MACE: Death, MI, and TVR) |
13 | — |
| SECONDARY Long-term Clinical Outcomes: Composite Major Adverse Cardiac Events (MACE: Death, MI, and TVR) |
13 | — |
Summary
The purpose of this study is to compare FFR measurements done with adenosine to FFR measurements done with contrast, where the contrast is injected using the ACIST CVi automated contrast injector.
The ACCELERATION study will support a safer approach to FFR for patients by potentially reducing toxic drug exposure (adenosine). The 2 main objectives of the study are:
1. Perform a methods comparison between cFFR and the reference standard aFFR, where cFFR is performed using an automated injector with a standardized volume and rate of delivery of contrast with known osmolality.
2. Evaluate the association between final post-PCI FFR and long-term clinical outcomes. The long-term clinical outcomes will include TVR and composite MACE (death, MI, and TVR) at 30 days and 1 year.
Eligibility Criteria
Inclusion Criteria
- Have the capacity to understand and sign an informed consent or have a legally authorized representative (LAR) that can understand and sign an informed consent prior to initial arteriotomy access
- Age > 18 years of age at the time of signing the informed consent
- Clinically stable and undergoing non-emergent cardiac catheterization for appropriate indications
- Willing to be contacted by telephone at 30 days (if no standard of care visit) and at 1 year with chart review for events.
- Target vessel with an intermediate lesion of 40-70% stenosis by angiographic assessment (a visual estimation by the operator). Serial lesions, diffuse disease, or ostial lesions ("all-comer" lesions) are acceptable if the operator would normally perform FFR and proceed with PCI (or other revascularization) if positive.
Exclusion Criteria
- Any condition associated with a life expectancy of less than 1 year
- Participation in another clinical study using an investigational agent or device within the past 3 months
- Ejection fraction ≤ 35%
- Creatinine ≥ 2
- Severe valvular heart disease
- Decompensated acute diastolic or systolic heart failure
- Bronchospastic chronic obstructive pulmonary disease or other intolerance to adenosine
- ST-segment elevation myocardial infarction culprit lesion or lesions with any thrombus burden after diagnostic angiography
- Lesions with severe calcification after diagnostic angiography
- Lesions in a target vessel supplied by a patent graft
Data sourced from ClinicalTrials.gov (NCT03557385). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.